2006
Drug-Eluting Stents in the Treatment of Intermediate Lesions Pooled Analysis From Four Randomized Trials
Moses JW, Stone GW, Nikolsky E, Mintz GS, Dangas G, Grube E, Ellis SG, Lansky AJ, Weisz G, Fahy M, Na Y, Russell ME, Donohoe D, Leon MB, Mehran R. Drug-Eluting Stents in the Treatment of Intermediate Lesions Pooled Analysis From Four Randomized Trials. Journal Of The American College Of Cardiology 2006, 47: 2164-2171. PMID: 16750680, DOI: 10.1016/j.jacc.2006.01.068.Peer-Reviewed Original ResearchConceptsMajor adverse cardiac eventsDrug-eluting stentsTarget vessel revascularizationIntermediate lesionsAngiographic restenosisMyocardial infarctionCardiac deathStent thrombosisDe novo coronary artery lesionsIntroduction of DESLate major adverse cardiac eventsEfficacy of DESNovo coronary artery lesionsBinary angiographic restenosisAdverse cardiac eventsCoronary artery lesionsCurrent treatment paradigmsTreatment of patientsIntermediate coronary lesionsBalloon-expandable stentsLower ratesEverolimus trialsRestenosis reductionTAXUS IVVessel revascularization
2004
Six- and Twelve-Month Results From First Human Experience Using Everolimus-Eluting Stents With Bioabsorbable Polymer
Grube E, Sonoda S, Ikeno F, Honda Y, Kar S, Chan C, Gerckens U, Lansky AJ, Fitzgerald PJ. Six- and Twelve-Month Results From First Human Experience Using Everolimus-Eluting Stents With Bioabsorbable Polymer. Circulation 2004, 109: 2168-2171. PMID: 15123533, DOI: 10.1161/01.cir.0000128850.84227.fd.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnticoagulantsCatheterizationCineangiographyCoated Materials, BiocompatibleComorbidityCoronary AngiographyCoronary RestenosisCoronary StenosisDrug ImplantsEverolimusFemaleFollow-Up StudiesGrowth InhibitorsHumansHyperplasiaImmunosuppressive AgentsLactic AcidMaleMiddle AgedMyocardial InfarctionPolyestersPolymersProspective StudiesSingle-Blind MethodSirolimusStainless SteelStentsTreatment OutcomeTunica IntimaUltrasonography, InterventionalConceptsEverolimus-eluting stentsBare metal stentsRestenosis rateMajor adverse cardiac event ratesAdverse cardiac event ratesDe novo coronary lesionsMajor adverse cardiac eventsPercent neointimal volumeSegment restenosis rateAdverse cardiac eventsCardiac event rateNovo coronary lesionsStent restenosis rateTwelve-month resultsFirst human experienceIntravascular ultrasound analysisInitial clinical experienceLate stent malappositionLate stent thrombosisStent neointimal hyperplasiaSignificant reductionRestenosis reductionCardiac eventsI trialCoronary lesions